AVA-001 is under clinical development by Avalon GloboCare and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVA-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVA-001 overview

AVA-001 is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin’s lymphoma (NHL). The therapy constitutes of genetically manipulated autologous T cells which express a chimeric antigen receptor targeting cells expressing B lymphocyte antigen CD19 (CD-19).

Avalon GloboCare overview

Avalon GloboCare (AVCO) provides healthcare management and biotechnology development services through its core platforms. It also provides strategic advisory and outsourcing services. The company is headquartered in Freehold, New Jersy, the US.

For a complete picture of AVA-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.